Gastric Cancer Research Reveals Promising MicroRNA Study

A recent study conducted at the Shiraz University of Medical Sciences in Shiraz, Iran, has shed light on the role of microRNAs (miRNAs) in gastric cancer. The research, which involved 30 gastric cancer patients, aimed to investigate the expression levels of miR-503-5p in the serum of patients before and after chemotherapy. The study found a significant increase in miR-503-5p expression post-treatment, with a 2.12-fold increase (P=0.001).

Key Takeaways:

• Gastric cancer is the third most fatal cancer among all cancer types, with early diagnosis significantly increasing the five-year survival rate of patients.
• MicroRNAs (miRNAs) play a crucial role in tumorigenesis, angiogenesis, invasion, metastasis, and drug resistance in gastric cancer.
• The study found a significant correlation between miR-503-5p expression and clinicopathological characteristics in gastric cancer patients.
• The expression levels of miR-503-5p in the serum of patients with metastasis were significantly lower than those without metastasis (P<0.05).
• The study's findings suggest that miR-503-5p may be a potential biomarker for the diagnosis and prognosis of gastric cancer.

Statistics:

• 30 patients with gastric cancer were included in the study, with no prior treatment before enrollment.
• The study found a 2.12-fold increase in miR-503-5p expression post-treatment (P=0.001).
• The expression levels of miR-503-5p in the serum of patients with metastasis were significantly lower than those without metastasis (P<0.05).
• The study was conducted at Namazi and Shahid Faghihi Hospitals from 2022 to 2024.

Sources:

• A Cross-Sectional Study Comparing Mir-503-5p Expression in Gastric Cancer Patients Before and After Chemotherapy. Iranian Journal of Colorectal Research, 2024, 12(4):117-122.